TcL Pharma has chosen Lonza to manufacture its lead monoclonal antibody. Lonza will provide strain development using its XS Microbial Expression Technologies through to cGMP manufacture of Phase I clinical material.
Manufacturing Chemist
Thursday 5 March 2009
Lonza to manufacture TcL Pharma antibody
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment